4-(4-氯苯甲酰基)苯甲酰氯 | 81928-54-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-氯苯甲酰基)苯甲酰氯
• 英文名称: 4-(4-chlorobenzoyl)benzoyl chloride
• 英文别名: 4-(4-chlorobenzoyl)benzoic acid；4(4'-chlorobenzoyl)-benzoyl chloride
• CAS: 81928-54-3
• 化学式: C₁₄H₈Cl₂O₂
• 分子量: 279.122
• InChiKey: DUXJMJIEXYFFFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-氯苯甲酰基)苯甲酰氯 在 三甲氧基磷 作用下， 以 氯仿 、 Petroleum ether 为溶剂， 生成 dimethyl 4-(4-chlorobenzoyl)benzoylphosphonate
  参考文献：
  名称：

  Anti-atherosclerotic pharmaceutical compositions containing

  摘要：

  本发明涉及一种制药组合物，用于增加循环高密度脂蛋白的相对数量，有利于增加α/β脂蛋白胆固醇比率，清除某些组织中的胆固醇和脂质，并诱导降压活性，包括向人体内给予化合物的有效量，该化合物的化学式为：##STR1## 其中X为H，OH或##STR2## R和R'相同或不同，为H，CH.sub.3或C.sub.2H.sub.5；m为零或1；A选自包括(CH.sub.3).sub.3C--，Y--C.sub.6H.sub.4--，Y--C.sub.6H.sub.4--O--C(CH.sub.3).sub.2--，Y--C.sub.6H.sub.4--C(CH.sub.3).sub.2--，Y--C.sub.6H.sub.4--C(O)--C.sub.6H.sub.4--，Y--C.sub.6H.sub.4--(CH.sub.2).sub.n--和Y--C.sub.6H.sub.4--O--(CH.sub.2).sub.n--，其中n为1至6的整数，Y为H，CH.sub.3，OCH.sub.3，卤素和药学上可接受的辅料。

  公开号：

  US04416877A1
• 作为产物：
  描述：

  4-氯-4-甲基苯甲酮 在 Jones reagent 、 氯化亚砜 作用下， 以 溶剂黄146 为溶剂， 反应 6.0h， 生成 4-(4-氯苯甲酰基)苯甲酰氯
  参考文献：
  名称：

  Penicillin inhibitors of purple acid phosphatase

  摘要：

  Purple acid phosphatases (PAPs) are binuclear metallohydrolases that have a multitude of biological functions and are found in fungi, bacteria, plants and animals. In mammals, PAP activity is linked with bone resorption and over-expression can lead to bone disorders such as osteoporosis. PAP is therefore an attractive target for the development of drugs to treat this disease. A series of penicillin conjugates, in which 6-aminopenicillanic acid was acylated with aromatic acid chlorides, has been prepared and assayed against pig PAP. The binding mode of most of these conjugates is purely competitive, and some members of this class have potencies comparable to the best PAP inhibitors yet reported. The structurally related penicillin G was shown to be neither an inhibitor nor a substrate for pig PAP. Molecular modelling has been used to examine the binding modes of these compounds in the active site of the enzyme and to rationalise their activities. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.123

文献信息

• gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity
  作者：Nguyen Lan Mong、Eric Niesor、Craig L. Bentzen

  DOI：10.1021/jm00391a027

  日期：1987.8

  New diphosphonate compounds and related derivatives were synthesized and investigated for their activity in specifically inducing plasma high density lipoproteins (HDL) and high density lipoprotein cholesterol (HDL-C) in normal rats. The screening of numerous compounds has permitted the determination of the structural variations leading to optimal plasma lipid altering activity, indicating antiatherosclerotic potential. Among the compounds observed to be the most active, dimethyl alpha-(dimethoxyphosphinyl)-p-chlorobenzyl phosphate (20, SR-202, mifobate) was selected for further pharmacological and subsequent clinical development.
• Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines
  申请人：ROHM AND HAAS COMPANY

  公开号：EP0639559B1

  公开（公告）日：1997-10-15
• NGUYEN, LAN M.;NIESOR, ERIC;BENTZEN, CRAIG L., J. MED. CHEM., 30,(1987) N 8, 1426-1433
  作者：NGUYEN, LAN M.、NIESOR, ERIC、BENTZEN, CRAIG L.

  DOI：——

  日期：——
• Diphosphonate or phosphate-phosphonate derivatives and pharmaceutical compositions containing them
  申请人：SYMPHAR S.A.

  公开号：EP0015370B1

  公开（公告）日：1983-01-12
• US4309364A
  申请人：——

  公开号：US4309364A

  公开（公告）日：1982-01-05